Daiichi Sankyo Company, Limited (DSNKY)
OTCMKTS
· Delayed Price · Currency is USD
24.15
-0.40 (-1.63%)
Jun 6, 2025, 1:07 PM EDT
Daiichi Sankyo Company Employees
Daiichi Sankyo Company had 18,726 employees as of March 31, 2024. The number of employees increased by 1,291 or 7.40% compared to the previous year.
Employees
18,726
Change (1Y)
1,291
Growth (1Y)
7.40%
Revenue / Employee
$672,658
Profits / Employee
$105,470
Market Cap
44.90B
Employees Chart
Employees History
Related Stocks
| Company Name | Employees |
|---|---|
| Endo Inc. | 3,116 |
| Tian'an Technology Group | 8 |
| Elite Pharmaceuticals | 64 |
| Glass House Brands | 374 |
| CytoDyn | 9 |
| Northwest Biotherapeutics | 25 |
| American Oncology Network | 1,914 |
| Silence Therapeutics | 116 |
Daiichi Sankyo Company News
- 5 days ago - ENHERTU® (fam-trastuzumab deruxtecan-nxki) plus pertuzumab reduced the risk of disease progression or death by 44% vs. THP as 1st-line therapy in patients with HER2-positive metastatic breast cancer in DESTINY-Breast09 Phase III trial - Benzinga
- 5 days ago - ENHERTU® Plus Pertuzumab Reduced the Risk of Disease Progression or Death by 44% Versus THP as First-Line Therapy in Patients with HER2 Positive Metastatic Breast Cancer in DESTINY-Breast09 Phase 3 Trial - Benzinga
- 6 days ago - DATROWAY® Continues to Show Promising Tumor Responses as Part of Combination Regimens in Patients with Early and Advanced Non-Small Cell Lung Cancer - Benzinga
- 7 days ago - ENHERTU® Reduced the Risk of Death by 30% Versus Ramucirumab Plus Paclitaxel as a Second-Line Therapy in Patients with HER2 Positive Unresectable or Metastatic Gastric Cancer in DESTINY-Gastric04 Phase 3 Trial - Benzinga
- 9 days ago - Merck, Daiichi Sankyo pull marketing application for lung cancer therapy - Seeking Alpha
- 16 days ago - Daiichi Sankyo Continues to Transform Treatment Landscape for Patients with Cancer with Practice-Changing Data at ASCO - Business Wire
- 17 days ago - AstraZeneca's record seventh year of plenary data at ASCO furthers ambition to redefine breast cancer care and transform outcomes in gastric cancer - Benzinga
- 23 days ago - Merck Announces Phase 3 KEYNOTE-B96 Trial Met Primary Endpoint of Progression-Free Survival (PFS) in Patients With Platinum-Resistant Recurrent Ovarian Cancer Whose Tumors Expressed PD-L1 and in All Comers - Benzinga